KORU Medical Systems, Inc. Announces Development Agreement For Next-Generation Subcutaneous Immunoglobulin Infusion System
Portfolio Pulse from Benzinga Newsdesk
KORU Medical Systems, Inc. (NASDAQ:KRMD) has announced a development agreement with a biopharmaceutical manufacturer to develop and seek regulatory approval for a next-generation infusion system for its subcutaneous immunoglobulin (SCIg) therapy. The new system is intended to facilitate easier home therapy and allow pharmacies to use one pump for their SCIg patients, regardless of whether the drug is provided in a vial or prefilled syringe.
November 08, 2023 | 10:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KORU Medical's new development agreement for a next-generation infusion system could potentially boost its market position and revenues, given the system's potential to simplify home therapy for SCIg patients.
The development of a next-generation infusion system could potentially increase KORU Medical's market share and revenues by simplifying home therapy for SCIg patients. This could lead to increased demand for KORU's products, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100